Deal facts
- Buyer
- WATERS
- Target
- BD (BIOSCIENCES AND DIAGNOSTIC SOLUTIONS BUSINESSES)
- Deal value
- Not disclosed
- Announced
- 29 October 2025
- Status
- In review
- Sector
- Healthcare
- Country
- Not stated
- Consideration
- Not stated
Sources
WATERS has agreed to acquire the BIOSCIENCES AND DIAGNOSTIC SOLUTIONS BUSINESSES of BD in a strategic acquisition announced on 29 October 2025. The transaction involves the purchase of specific business units within the target organisation, operating within the NaceV2Sector_C_32.50 classification. No financial consideration or deal value was disclosed in the available information regarding this transaction. The buyer intends to integrate these assets into its existing portfolio to expand its capabilities in the relevant sector.
The deal remains subject to regulatory approval and other customary closing conditions before completion. As of the latest update, the transaction status is recorded as in review. No completion date has been confirmed at this stage. The parties are currently proceeding through the necessary regulatory processes required to finalise the agreement. Further details regarding the specific terms of the arrangement have not been made public.
Weekly digest
Join Exit Mode Insider
Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.
Join Exit Mode Insider, £12/moDeal timeline
1 update- CMA invitation to comment
WATERS to acquire BD (BIOSCIENCES AND DIAGNOSTIC SOLUTIONS BUSINESSES)
WATERS to acquire BD (BIOSCIENCES AND DIAGNOSTIC SOLUTIONS BUSINESSES)
EU DG COMP
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.
Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.
- Buyer
- Shuttle Pharmaceuticals Holdings, Inc.
- Target
- United Dogecoin Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MedPal AI plc to acquire Remedi Solutions Limited
MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.
- Buyer
- MedPal AI plc
- Target
- Remedi Solutions Limited
- Deal value
- GBP 310,000
- Deal type
- strategic acquisition
BIOMARIN PHARMACEUTICAL INC to acquire Amicus
BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.
- Buyer
- BIOMARIN PHARMACEUTICAL INC
- Target
- Amicus
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.
- Buyer
- Telomir Pharmaceuticals, Inc.
- Target
- TELI Pharmaceuticals, Inc.
- Deal value
- USD 34,389,710
- Deal type
- strategic acquisition
GSK plc to acquire 35Pharma Inc.
GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…
- Buyer
- GSK plc
- Target
- 35Pharma Inc.
- Deal value
- USD 950,000,000
- Deal type
- strategic acquisition
Buyer history
WATERS
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive
